Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of KB304, a Replication-Defective, Non-Integrating Vector Expressing Human Type III Collagen (COL3) and Tropoelastin for the Treatment of Wrinkles

NCT06724900 is registered in ClinicalTrials.gov with Krystal Biotech, Inc. as lead sponsor.

NCT NCT06724900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06724900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of KB304, a Replication-Defective, Non-Integrating Vector Expressing Human Type III Collagen (COL3) and Tropoelastin for the Treatment of Wrinkles
Lead sponsor
Krystal Biotech, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 20, 2024
Completion date
August 31, 2025
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

décolleté wrinkles, pigmentation, wrinkles in decolletage